UAE Founded in July 2020, the Emirates Health Economics Society – led by Dr Sara Al Dallal – aims to create a space for the discussion of health economics within the UAE. In conversation with PharmaBoardroom, Dr Al Dallal outlines how the organisation’s collaborations with governmental, industry, and academic stakeholders are…
Global Speaking as GM and head of the Middle East, Turkey, and Africa region, Andrew Bird, who has since become Acino’s Interim Chief Executive Officer, discusses the Swiss company’s “being global but acting local” approach to emerging markets and outlines the importance of the META region, which accounts for 35 percent…
USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…
USA Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow Medicare to negotiate prices for the drugs it spends the most on as of 2026. Viehbacher, who was brought in…
Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…
Egypt AbbVie’s GM for Egypt & Levant, Ali Sleiman, explains the factors behind the stellar growth that has made the cluster one of the company’s fastest-growing global markets in 2021. He also discusses the favourable environment created by Egypt’s healthcare reforms and how they have quickened regulatory approvals and access, leading…
Switzerland The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over five million more likely to follow. Elsewhere, Swiss health insurance premiums are set to see their largest rise since 2010…
China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals. Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…
Egypt Amgen’s country director for the ELI cluster (Egypt, Levant, and Iran), Ahmed Kishta, dives into the dynamics shaping the Egyptian market, Egypt’s Vision 2030 and how Amgen is contributing to the health of Egyptian patients. The effort to transform healthcare in Egypt has been tremendous during the last 5-6…
Spain After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any other region. The birthplace of many of the country’s pharma success stories, Catalonia boasts a strong scientific output by European…
Global With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year. Pfizer to take the lead, followed by Merck, and possibly, Shionogi. According to Airfinity’s recent COVID-19 treatment revenue forecast, the…
MEA The Middle East and Africa, combined, represent the world’s fifth largest regional pharma market. According to IQVIA’s recent figures, most of the largest markets grew, although slowly due to COVID lockdowns, with Saudi Arabia in the top position. Multinational companies continue to “dominate” the region with Gilead Sciences experiencing huge…
See our Cookie Privacy Policy Here